In Part I, we explored how new research from Karolinska Institutet revealed that the brain keeps generating neurons well into old age. Biology says growth continues. Culture still says decline is inevitable. That mismatch makes mindset the true starting point of the longevity revolution.
But mindset is only the beginning. If the brain is capable of renewal, what about the rest of the body? What happens when we move from growing minds to extending lives?
The Billionaire Bet on Longevity
How much would you invest in the possibility of living to 150, or simply having 20 extra healthy years? For the ultra-wealthy, the answer is clear: more than $5 billion has been poured into longevity deals over the past 25 years, according to a Wall Street Journal analysis of PitchBook, company filings, and regulatory data.
That number is staggering. It signals that longevity is not science fiction. It’s a marketplace, one already being built and funded by those with the means to secure their place in line.
Biotech Bets on Ten More Years
Among the boldest players is Retro Biosciences, the biotech company backed by Sam Altman, CEO of OpenAI. Altman invested US$180 million of his own capital into Retro, which aims to add ten healthy years to the human lifespan. Their work spans cellular reprogramming, plasma-based therapies, and interventions targeting age-related diseases of the blood and brain. It reflects the same principle that Karolinska confirmed about the brain: decline is not destiny. Systems can be repaired. Lifespan can be extended. Healthspan can be protected.
The Risk Without AAA
But a hard truth remains: who gets those extra ten years?
If breakthroughs like Retro’s stay locked behind wealth, the world risks creating a new divide – longevity inequality, one that could grow even faster than economic inequality.
This is where AAA – Affordability, Availability, and Accessibility must become the north star for policymakers and industry.
History shows us what happens when AAA is ignored. Take cancer medicine. In 2019 alone, U.S. patients spent over US$21 billion out-of-pocket on cancer care, including US$3.14 billion for breast cancer, US$2.26 billion for prostate cancer, US$1.46 billion for colorectal cancer, and US$1.35 billion for lung cancer (NIH).
Governments and insurers had decades to prepare, yet millions were priced out or shut out of lifesaving therapies. Now, thanks to AI accelerating drug discovery, biotech timelines are shortening dramatically. What once took decades may take only years. This time, society won’t have the luxury of slow adaptation. Unless AAA is embedded from the start, longevity therapies risk deepening inequality faster than any financial system ever has.
Innovation Meets Policy
This is why innovation and policy must go hand in hand. It is not enough for people to believe they can grow; society must ensure the tools of growth are fairly distributed. Otherwise, we risk a cruel paradox: a world where science proves ageing can be slowed, but only for those who can pay. The longevity revolution cannot be a luxury good. It must be a shared infrastructure as essential as clean water, energy, or education.
Closing With a Moral Imperative
And here, David Sinclair’s words cut through the noise: “In my mind, there are few sins so egregious as extending life without health. … We have an absolute moral obligation to do the latter.” — Lifespan: Why We Age — and Why We Don’t Have To
The billionaires may be buying the future. Biotech may be building it. But the true test is whether that future is healthy and whether it belongs to all of us, not just the wealthy few.
What Comes Next
This brings us to the next frontier: compounding in longevity, a concept Sinclair has championed. Gains in lifespan and healthspan don’t just add up, they multiply. Small interventions ripple across decades, shaping not only biology but also economics, climate, and purpose.
In Part III, we’ll explore longevity compounding — and what it means for our collective future.
